A Randomized Crossover Trial of Combination Pharmacologic Therapy in Children with Familial Hyperlipidemia

We sought to determine whether a low-dose combination of a bile acid–binding resin (colestipol) with an hydroxymethylglutaryl CoA reductase inhibitor (pravastatin) would result in improved acceptability, compliance, and effectiveness in lipid-lowering compared with conventional therapy with a higher dose of a bile acid–binding resin only, with fewer side effects. We performed a randomized, crossover open-label clinical trial with two 18-wk …